We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+20.34%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.16B
AUM Growth
+$284M
Cap. Flow
+$60M
Cap. Flow %
1.44%
Top 10 Hldgs %
34.47%
Holding
129
New
1
Increased
41
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25M
3
BAX icon
Baxter International
BAX
+$21.2M
4
BPMC
Blueprint Medicines
BPMC
+$16.9M
5
IRON icon
Disc Medicine
IRON
+$16.9M

Top Sells

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$35.1M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$16.4M
3
ARVN icon
Arvinas
ARVN
+$12.5M
4
GOSS icon
Gossamer Bio
GOSS
+$9.97M
5
OHPAU
Orion Acquisition Corp. Unit
OHPAU
+$9.87M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
2 Consumer Staples 0.83%
3 Industrials 0.36%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRX
101
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.18M 0.05%
437,329
– –
AUPH icon
102
Aurinia Pharmaceuticals
AUPH
$2.04B
$2.07M 0.05%
479,540
-586,868
-55% -$3.41M
SPRB
103
Spruce Biosciences
SPRB
$129M
$1.78M 0.04%
21,636
– –
CYPH
104
Cypherpunk Technologies Inc
CYPH
$71.5M
$1.65M 0.04%
365,985
– –
SYRE icon
105
Spyre Therapeutics
SYRE
$8.9B
$1.54M 0.04%
136,556
– –
EPIX
106
DELISTED
ESSA Pharma
EPIX
$1.32M 0.03%
524,944
– –
SPRO icon
107
Spero Therapeutics
SPRO
$70.6M
$1.16M 0.03%
669,533
-101,177
-13% -$189K
FATE icon
108
Fate Therapeutics
FATE
$316M
$1.11M 0.03%
110,000
– –
TPST icon
109
Tempest Therapeutics
TPST
$17.1M
$947K 0.02%
63,358
– –
CGEN icon
110
Compugen
CGEN
$228M
$923K 0.02%
1,289,990
– –
VINC
111
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$910K 0.02%
44,586
-10,843
-20% -$204K
GOSS icon
112
Gossamer Bio
GOSS
$86.7M
$816K 0.02%
376,048
-1,210,914
-76% -$9.97M
TLPH icon
113
Talphera
TLPH
$73.7M
$715K 0.02%
316,460
– –
APLT
114
DELISTED
Applied Therapeutics
APLT
$453K 0.01%
596,680
-105,000
-15% -$83K
BCEL
115
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$290K 0.01%
362,530
-100,000
-22% -$127K
NUVB.WS
116
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$19.4K ﹤0.01%
134,028
– –
ALT icon
117
CALL
Altimmune
ALT
$591M
– –
-33,500
Closed -$428K
ARVN icon
118
Arvinas
ARVN
$581M
– –
-280,100
Closed -$12.5M
ELVN icon
119
Enliven Therapeutics
ELVN
$4.26B
– –
-210,601
Closed -$1.92M
EQRX
120
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-1,000,000
Closed -$4.95M
OHPAU
121
DELISTED
Orion Acquisition Corp. Unit
OHPAU
– –
-1,000,000
Closed -$9.87M
JYAC
122
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
– –
-206,200
Closed -$2.06M
PHAS
123
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-2,719,074
Closed -$479K
BLSA
124
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
– –
-309,000
Closed -$3.1M
CVET
125
DELISTED
Covetrus, Inc. Common Stock
CVET
– –
-1,678,800
Closed -$35.1M
1 2 3 4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rock Springs Capital Management held 129 positions worth $4.16B, up 7.3% from $3.87B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management's Q4 2022 filing shows 1 new, 41 increased, 24 reduced and 9 closed positions. Its largest new stake was Disc Medicine: 339,497 shares worth $6.75M. The largest sale was Covetrus, Inc. Common Stock, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2022 buy was Disc Medicine: 339,497 shares worth $6.75M.
  • Rock Springs Capital Management added most to Amylyx Pharmaceuticals in Q4 2022, an estimated $29.3M increase.
  • Rock Springs Capital Management's biggest Q4 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $16.4M.
  • Rock Springs Capital Management fully exited Covetrus, Inc. Common Stock in Q4 2022, selling an estimated $35.1M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.16B portfolio in Q4 2022.
  • Rock Springs Capital Management opened 1 new position and closed 9 in Q4 2022.
  • Rock Springs Capital Management's portfolio value rose 7.3% quarter-over-quarter to $4.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.